238 related articles for article (PubMed ID: 27864694)
1. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.
Bear HD; Tang G; Rastogi P; Geyer CE; Zoon CK; Kidwell KM; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N
Ann Surg Oncol; 2017 Jul; 24(7):1853-1860. PubMed ID: 27864694
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction.
Kansal KJ; Dominici LS; Tolaney SM; Isakoff SJ; Smith BL; Jiang W; Brock JE; Winer EP; Krop IE; Golshan M
Breast Cancer Res Treat; 2013 Sep; 141(2):255-9. PubMed ID: 24026859
[TBL] [Abstract][Full Text] [Related]
3. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Blum JL; Flynn PJ; Yothers G; Asmar L; Geyer CE; Jacobs SA; Robert NJ; Hopkins JO; O'Shaughnessy JA; Dang CT; Gómez HL; Fehrenbacher L; Vukelja SJ; Lyss AP; Paul D; Brufsky AM; Jeong JH; Colangelo LH; Swain SM; Mamounas EP; Jones SE; Wolmark N
J Clin Oncol; 2017 Aug; 35(23):2647-2655. PubMed ID: 28398846
[TBL] [Abstract][Full Text] [Related]
4. Does neoadjuvant bevacizumab increase surgical complications in breast surgery?
Golshan M; Garber JE; Gelman R; Tung N; Smith BL; Troyan S; Greenberg CC; Winer EP; Ryan P
Ann Surg Oncol; 2011 Mar; 18(3):733-7. PubMed ID: 20882415
[TBL] [Abstract][Full Text] [Related]
5. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44).
Gerber B; von Minckwitz G; Eidtmann H; Rezai M; Fasching P; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Solbach C; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Nekljudova V; Loibl S; Untch M
Ann Surg Oncol; 2014 Aug; 21(8):2517-24. PubMed ID: 24740826
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
7. Surgical site infection in immediate breast reconstruction: Does chemotherapy timing make a difference?
Chattha AS; Cohen JB; Bucknor A; Chen AD; Tobias AM; Lee BT; Lin SJ
J Surg Oncol; 2018 Jun; 117(7):1440-1446. PubMed ID: 29574751
[TBL] [Abstract][Full Text] [Related]
8. Surgical complications of skin sparing mastectomy and immediate prosthetic reconstruction after neoadjuvant chemotherapy for invasive breast cancer.
Donker M; Hage JJ; Woerdeman LA; Rutgers EJ; Sonke GS; Vrancken Peeters MJ
Eur J Surg Oncol; 2012 Jan; 38(1):25-30. PubMed ID: 21963981
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
[TBL] [Abstract][Full Text] [Related]
11. Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction.
Warren Peled A; Itakura K; Foster RD; Hamolsky D; Tanaka J; Ewing C; Alvarado M; Esserman LJ; Hwang ES
Arch Surg; 2010 Sep; 145(9):880-5. PubMed ID: 20855759
[TBL] [Abstract][Full Text] [Related]
12. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.
Cortés J; Caralt M; Delaloge S; Cortes-Funes H; Pierga JY; Pritchard KI; Bollag DT; Miles DW
Eur J Cancer; 2012 Mar; 48(4):475-81. PubMed ID: 22196033
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
[TBL] [Abstract][Full Text] [Related]
14. The impact of skin-sparing mastectomy with immediate reconstruction in patients with Stage III breast cancer treated with neoadjuvant chemotherapy and postmastectomy radiation.
Prabhu R; Godette K; Carlson G; Losken A; Gabram S; Fasola C; O'Regan R; Zelnak A; Torres M
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e587-93. PubMed ID: 22197232
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Autologous Breast Reconstruction Complications by Type of Neoadjuvant Chemotherapy Regimen.
Olawoyin OM; Mehta S; Chouairi F; Gabrick KS; Avraham T; Pusztai L; Alperovich M
Plast Reconstr Surg; 2021 Dec; 148(6):1186-1196. PubMed ID: 34644277
[TBL] [Abstract][Full Text] [Related]
16. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
17. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
18. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
Zielinski C; Lang I; Beslija S; Kahan Z; Inbar MJ; Stemmer SM; Anghel R; Vrbanec D; Messinger D; Brodowicz T
Br J Cancer; 2016 Jan; 114(2):163-70. PubMed ID: 26657657
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
